AEOL 11114

Drug Profile

AEOL 11114

Alternative Names: AEOL 11114B; AEOL11114

Latest Information Update: 18 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Jewish Medical and Research Center; University of Colorado at Anschutz Medical Campus
  • Class Antiparkinsonians; Glyoxylates; Metalloporphyrins; Porphyrins
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 31 Mar 2016 Aeolus receives patent allowance for AAEOL 11114 in Japan prior to March 2016
  • 02 Nov 2015 AEOL 11114 licensed to Aeolus worldwide for the treatment of Parkinson's disease
  • 02 Nov 2015 Aeolus receives patent allowance for AAEOL 11114 in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top